Permeation Enhancers for Oral Peptides

Oral Peptide Delivery

~1% bioavailability

Even with permeation enhancers, oral peptide bioavailability typically reaches only 0.4-1%, requiring dramatically higher doses than injectable forms.

Brayden et al., Expert Opinion on Drug Delivery, 2021

Brayden et al., Expert Opinion on Drug Delivery, 2021

View as image

Most peptide drugs cannot survive the journey from mouth to bloodstream. Stomach acid degrades them, digestive enzymes shred them, and the intestinal epithelium blocks their passage. The gut wall is a barrier designed to keep large molecules out. Permeation enhancers are the chemical keys that temporarily open this barrier, allowing peptide drugs to cross into circulation. Two FDA-approved oral peptide drugs, semaglutide (Rybelsus) and octreotide (Mycapssa), owe their existence to permeation enhancer technology. For context on why oral peptide delivery is so difficult, see why you can't just swallow most peptides. For how the field's leading example works, see how SNAC makes oral semaglutide possible. For the broader pipeline, see our pillar article on the future of oral peptide drugs.

The Gut Wall as a Drug Barrier

The intestinal epithelium is a single layer of cells connected by tight junctions that controls what passes from the gut lumen into the bloodstream. Small lipophilic molecules (aspirin, ibuprofen) cross this barrier readily by dissolving through cell membranes. Peptide drugs cannot. They are too large (typically 500-5,000 daltons), too polar (covered in hydrogen bond donors and acceptors), and too hydrophilic to pass through lipid bilayer membranes.

Two routes exist for molecules to cross the epithelium: transcellular (through cells) and paracellular (between cells through tight junctions). Peptides are excluded from both. The transcellular route rejects them because their polarity prevents membrane dissolution. The paracellular route rejects them because tight junctions have a size cutoff of approximately 10-15 angstroms, far smaller than most therapeutic peptides.

Permeation enhancers overcome these barriers through several mechanisms: disrupting membrane lipid organization to enable transcellular passage, transiently loosening tight junctions to widen the paracellular route, or some combination of both. The key requirement is that these effects must be reversible. Permanent barrier disruption would expose the body to gut bacteria and toxins.

SNAC: The Technology Behind Oral Semaglutide

Salcaprozate sodium (SNAC), chemically sodium N-[8-(2-hydroxybenzoyl)amino] caprylate, is the most clinically successful permeation enhancer. It enabled the 2019 FDA approval of oral semaglutide (Rybelsus), the first oral GLP-1 receptor agonist.

SNAC works through three concurrent mechanisms. First, it raises local gastric pH in the immediate vicinity of the tablet, creating a microenvironment that protects semaglutide from acid-mediated degradation. Second, SNAC shields the peptide from enzymatic breakdown by pepsin. Third, and most distinctively, SNAC enhances transcellular absorption across the stomach epithelium rather than the intestine.^[1]

This gastric absorption pathway was unexpected. Most oral drugs are absorbed in the small intestine. SNAC-semaglutide exploits a unique property of the stomach lining: its relatively sparse protease environment (compared to the duodenum) and its accessibility before the tablet disintegrates and disperses. A comprehensive review characterized this as ushering in "a new era for oral peptides," noting that the SNAC-semaglutide co-formulation was specifically designed for point-source concentration in the stomach rather than distributed intestinal absorption.^[2]

A 2025 study in Nature Communications provided the first detailed molecular mechanism for how SNAC assists peptide absorption. The researchers showed that SNAC creates transient defects in the epithelial cell membrane that allow polar peptides to pass through transcellularly. These membrane defects are reversible and close after SNAC is cleared, restoring barrier integrity.^[3]

The clinical pharmacokinetics reveal both the promise and the limitation of SNAC technology. Oral semaglutide achieves roughly 0.4-1% bioavailability relative to subcutaneous injection. To compensate, the oral dose (3, 7, or 14 mg) is dramatically higher than the injectable dose (0.25-1 mg). Absorption requires specific dosing conditions: the tablet must be taken on an empty stomach with no more than 4 ounces of water, and patients must wait at least 30 minutes before eating. These constraints exist because food, beverages, and other medications dilute the SNAC concentration and disrupt the localized gastric absorption mechanism.^[4]

Sodium Caprate (C10): The Intestinal Route

Sodium caprate (C10), a medium-chain fatty acid salt, is the most extensively studied intestinal permeation enhancer. Unlike SNAC, which works in the stomach, C10 enhances absorption in the small intestine through both transcellular and paracellular mechanisms.

In vivo studies demonstrated that C10 improves intestinal absorption of a GLP-1/GIP coagonist peptide by transiently opening tight junctions and disrupting membrane lipid organization. The effect is concentration-dependent and fully reversible within 1-2 hours after C10 is cleared from the intestinal lumen.^[5]

C10 is a component of the Transient Permeation Enhancer (TPE) technology developed by Chiasma (now Amryt) for oral octreotide (Mycapssa), approved by the FDA in 2020 for acromegaly. The TPE system combines C10 with an oily suspension in an enteric-coated capsule. The enteric coating protects the formulation through the stomach; in the small intestine, the capsule dissolves and releases C10 and octreotide together.^[6]

Oral octreotide via TPE technology achieves approximately 0.7% relative oral bioavailability. This required formulating 20 mg capsules to deliver the equivalent of 0.1 mg subcutaneous injections, a 200-fold dose increase. Despite this low efficiency, the approach was clinically successful because octreotide is potent enough that even 0.7% absorption produces therapeutic blood levels.^[6]

Combining Enhancers: SNAC Plus C10

If SNAC and C10 work through different mechanisms and at different absorption sites (stomach vs. intestine), could combining them improve bioavailability beyond what either achieves alone? Niu and colleagues tested this in a 2025 study, formulating oral tablets containing both SNAC and C10 for delivery of a GLP-1/GIP coagonist peptide.^[7]

In preclinical models, the combination produced higher dose-corrected area-under-the-curve (AUC) values than either enhancer alone. The rationale is that SNAC provides gastric absorption while C10 captures additional intestinal absorption, creating two sequential absorption windows. Early clinical pharmacokinetic data supported the preclinical findings.

This combination approach represents the current frontier of permeation enhancer development. However, doubling the number of excipients increases regulatory complexity, manufacturing costs, and the potential for gastrointestinal side effects.

How Permeation Enhancers Interact With Peptides

The interaction between permeation enhancers and their peptide cargo is more complex than simply "opening a door." Hossain and colleagues revealed that in the presence of intestinal bile salts, the molecular interactions between peptide drugs and permeation enhancers change substantially. Bile salts can compete with permeation enhancers for membrane binding sites, reducing their effectiveness. They can also form mixed micelles with enhancers that sequester the peptide away from the absorption surface.^[8]

This finding explains a persistent clinical observation: oral peptide absorption varies enormously between patients and between dosing occasions in the same patient. The bile salt concentration in the gut lumen fluctuates with diet, fasting state, and individual physiology. When bile salt levels are high, they antagonize the permeation enhancer; when low, the enhancer works more effectively. This variability is a fundamental limitation of permeation enhancer-based oral peptide delivery that no formulation strategy has fully solved.

Formulation strategies to optimize enhancer efficacy were reviewed comprehensively by Maher and colleagues. Enteric coatings protect enhancers through the stomach; mucoadhesive formulations extend contact time with the intestinal wall; timed-release systems synchronize enhancer and peptide release. Each strategy addresses a different failure mode, but none eliminates the underlying variability.^[9]

Developability Challenges

Berg and colleagues examined the practical considerations for developing oral peptides with permeation enhancers. The analysis was sobering: oral bioavailability for most peptides remains in single digits with high inter-patient variability. Only peptides with specific properties, high potency (therapeutic effect at nanomolar concentrations), reasonable stability (resistance to at least some proteases), and tolerance for dose escalation (safety margin allowing 100-200x dose increases), are candidates for oral delivery via permeation enhancers.^[10]

This narrows the applicable peptide universe considerably. Semaglutide and octreotide succeeded because they are exceptionally potent. Most peptide drug candidates are not. For peptides that require microgram-level blood concentrations for therapeutic effect, a 1% bioavailability pathway would demand impractically large oral doses.

Novel SNAC formulations are being explored to improve this picture. Shapira-Furman and colleagues synthesized SNAC phenolate salts that altered the absorption kinetics of semaglutide, suggesting that chemical modification of the enhancer itself could optimize performance.^[11] Salcaprozate-based ionic liquids showed faster gastric absorption of a GLP-1 analogue in rats compared to standard tablets, though awake dog studies revealed that gastric fluid dilution limited the in vivo advantage.^[12]

Safety Concerns: Microbiome Disruption

A 2026 study raised a new safety question. Ariaee and colleagues found that SNAC in oral semaglutide significantly disrupted gut microbiota composition and triggered systemic inflammation in rats. The microbiome perturbation was attributable to SNAC itself, independent of semaglutide's pharmacological effects. The inflammatory markers were dose-dependent and correlated with the degree of microbiome disruption.^[13]

This finding has implications beyond semaglutide. If permeation enhancers that disrupt epithelial membranes also disrupt the gut microbiome, then chronic daily dosing (as required for oral semaglutide) could produce cumulative effects on gut health. The clinical relevance in humans is unknown. Millions of patients take oral semaglutide daily, and no microbiome-related adverse signal has emerged from clinical trials or post-marketing surveillance. But the rat data warrant monitoring, particularly for patients on long-term therapy. For how oral semaglutide compares to injectable forms, see oral semaglutide (Rybelsus).

Next-Generation Permeation Enhancers

The field is moving beyond SNAC and C10. A 2024 review in Advanced Science surveyed gastrointestinal permeation enhancers "beyond sodium caprate and SNAC," cataloging emerging approaches including cell-penetrating peptides used as enhancers, bile acid derivatives, acylated amino acids, and synthetic surfactants designed for tunable and reversible membrane disruption.

Penetratin, a cell-penetrating peptide derived from the Drosophila Antennapedia homeodomain, has been evaluated as a non-invasive permeation enhancer for transmucosal peptide delivery. In vitro and ex vivo studies showed that penetratin enhanced peptide penetration across epithelial barriers without causing irreversible cellular damage.^[14]

Permeation enhancer-based ionogels represent another emerging platform. A 2025 study demonstrated an ionogel formulation that showed "remarkable potential for oral insulin delivery," combining the permeation-enhancing properties of ionic liquids with the sustained-release characteristics of gel matrices.^[15]

These next-generation approaches aim to solve the central paradox of permeation enhancers: the most effective barrier disruptors also carry the highest risk of tissue damage and systemic exposure to gut contents. The ideal enhancer would be potent enough to enable therapeutic absorption, selective enough to avoid damaging healthy tissue, and transient enough to restore barrier function within minutes.

Where Permeation Enhancers Stand

Two FDA-approved products (Rybelsus and Mycapssa) prove that permeation enhancers can enable oral peptide drugs. But both achieve less than 1% bioavailability, require strict dosing conditions, and work only with exceptionally potent peptides. The combination of SNAC and C10 may expand this slightly. The microbiome safety question raised by the 2026 rat study needs human investigation. And the fundamental challenge of inter-patient variability in absorption remains unsolved.

Permeation enhancers are not a universal solution to oral peptide delivery. They are a specific tool that works for a narrow class of peptides under constrained conditions. The broader oral peptide problem will likely require multiple complementary technologies: permeation enhancers paired with enteric coatings, enzyme inhibitors, and peptide engineering strategies like lipidation and PEGylation.

The Bottom Line

Permeation enhancers enable the only two FDA-approved oral peptide drugs: semaglutide (via SNAC) and octreotide (via sodium caprate/TPE technology). SNAC works by creating transient membrane defects in the stomach, while C10 loosens intestinal tight junctions. Both achieve less than 1% bioavailability. Combining SNAC and C10 shows promise in preclinical studies. A 2026 rat study raised concerns about SNAC-induced microbiome disruption. The field needs enhancers that are more potent, more selective, and more consistent across patients to expand oral peptide delivery beyond the current narrow window of exceptionally potent drugs.

Frequently Asked Questions

What is a permeation enhancer for oral peptides?

A permeation enhancer is a chemical excipient that temporarily increases the permeability of the intestinal or gastric epithelium, allowing peptide drugs to cross from the gut lumen into the bloodstream. SNAC (salcaprozate sodium) and sodium caprate (C10) are the two most clinically advanced examples, used in FDA-approved oral semaglutide and oral octreotide respectively. They work by disrupting cell membrane organization or loosening tight junctions between epithelial cells.

How does SNAC help oral semaglutide work?

SNAC enables oral semaglutide through three mechanisms: raising local gastric pH to protect the peptide from acid, shielding semaglutide from pepsin digestion, and creating transient membrane defects that allow the peptide to cross stomach epithelial cells transcellularly. A 2025 Nature Communications study provided the first molecular evidence for the membrane defect mechanism. Oral semaglutide achieves approximately 0.4-1% bioavailability, requiring doses 10-35 times higher than injectable.

What is the bioavailability of oral peptide drugs?

FDA-approved oral peptide drugs achieve 0.4-1% bioavailability relative to injectable forms. Oral semaglutide (Rybelsus) requires 14 mg oral to match 1 mg subcutaneous. Oral octreotide (Mycapssa) uses 20 mg capsules to match 0.1 mg injections, approximately 0.7% bioavailability. These low numbers mean that only highly potent peptides where massive dose escalation is safe and affordable are candidates for oral delivery via permeation enhancers.

Is SNAC safe for long-term use?

SNAC has been used in millions of oral semaglutide prescriptions since 2019 with no major safety signals in clinical trials or post-marketing surveillance. However, a 2026 rat study found that SNAC disrupted gut microbiota and triggered systemic inflammation independent of semaglutide's effects. The clinical relevance in humans is unknown. The most common side effects of oral semaglutide are gastrointestinal (nausea, diarrhea), though these are primarily attributed to semaglutide's pharmacology rather than SNAC.

What is sodium caprate used for in drug delivery?

Sodium caprate (C10) is a medium-chain fatty acid salt used as an intestinal permeation enhancer. It enables oral octreotide (Mycapssa) for acromegaly treatment by transiently opening tight junctions and disrupting membrane lipids in the small intestine. C10 is also being studied in combination with SNAC for next-generation oral peptide formulations. Its effects are fully reversible within 1-2 hours.

Why do oral peptide drugs require fasting?

Oral peptide drugs like semaglutide (Rybelsus) must be taken on an empty stomach because food, beverages, and other medications dilute the permeation enhancer concentration and disrupt the localized absorption mechanism. SNAC works by creating a concentrated microenvironment at the tablet surface; food and liquid in the stomach disperse both the SNAC and the peptide, dramatically reducing absorption. Patients must wait 30 minutes after dosing before eating.